Skip to main content
. 2017 Oct 30;71(1):1–9. doi: 10.1097/FJC.0000000000000551

FIGURE 3.

FIGURE 3.

Meta-analysis of clinical trials on levosimendan versus control in cardiac surgery patients with long-term and thirty-day mortality as primary outcome: Effects of levosimendan when used in case of severe perioperative cardiovascular dysfunction (LVEF ≤ 30%). Sensitivity analysis as in the supplemental material of Lee et al.47